Press Releases

iotaSciences and Quantum Design China Enter into Distribution Agreement

iotaSciences and Quantum Design China announced today an exclusive distribution agreement for iotaSciences proprietary single cell handling platforms in China.

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom study.

Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy

About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com About Ahead Therapeutics Ahead Therapeutics is a start-up biotech company that uses proprietary technology to develop treatments for different autoimmune disorders. Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing autoantigens. These liposomes can induce antigen-specific immune tolerance through a biomimetic process, thereby interrupting the autoimmune reaction. Simply by changing the encapsulated autoantigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others. For more information, please visit www.aheadtherapeutics.com Recipharm AB Corporate identity number 556498-8425 Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00 www.recipharm.com

GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting

GenNext Technologies, Inc. has announced the release of the AutoFox Protein Footprinting System at the California Separation Science Society combined Mass Spectrometry and Higher Order Structure meetings.

GenNext & SCIEX to Co-Market an Advanced High Order Structure Analysis (HOS) Workflow for Biopharmaceutical Research

GenNext Technologies, Inc. has revealed their agreement to co-market a robust, full-solution workflow for Hydroxyl Radical Protein Footprinting studies with SCIEX.

Blue Spark Technologies Adds Amir Lahav to Key Opinion Leader Advisory Group

Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, has added Amir Lahav, a clinical leader and established neuroscientist with 20 years of experience to its advisory board.

CD Genomics Revolutionizes Pathogen Discovery with the Launch of Viral Metagenomic Sequencing Service

CD Genomics Unveils A Pioneering Genomics Approach—Long Amplicon Analysis (LAA) Service

Dr. Vince Clinical Research, Clario Form Strategic Partnership to Deliver Innovative Cardiac Assessments in Clinical Trials

Dr. Vince Clinical Research (DVCR), an early phase Clinical Research Organization (CRO), today announced a new collaboration with Clario, a leading healthcare research and technology company that delivers leading endpoint technology solutions for clinical trials.

Barry Simms Named as Elligo Health Research’s Chief Operating Officer

Elligo Health Research®, the largest healthcare-enabling research organization, today announced the addition of Barry Simms as Elligo’s Chief Operating Officer (COO). Simms’ expertise in global strategy and partnerships will help further the company’s growth and mission of providing everyone with easy access to participation in research and to accelerate clinical trials along the way.

CD Genomics Launches Mature HLA Typing Solutions Enabling Precision Immune Profiling

Breaking Ground: CD Formulation announces 90+ Active Pharmaceutical Ingredients Lineup

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Kiora Pharmaceuticals, a clinical-stage biotechnology company developing products for the treatment of orphan retinal diseases, has been granted U.S. and European Patents for the local ocular delivery of the company’s non-steroidal, anti-inflammatory small molecules covering several inflammatory-related therapeutic applications including posterior non-infectious uveitis – a debilitating autoimmune disease characterized by inflammation of the retina, choroid, vitreous, or optic nerve that can lead to severe vision loss if left untreated.

ACS BrightEdge Poised to Help Improve 1.5 Million Lives By Investing in Cancer-Focused Therapies and Technologies

American Cancer Society's impact venture fund announces annual results and new framework that measures investments' impact on mission to end cancer

Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

Creative Proteomics Launches Advanced Exosome Isolation and Purification Service

Exploring New Frontiers in Drug Delivery: CD Formulation Introduces State-of-the-Art Microsphere and Microneedle Technologies

Creative Proteomics Debuts Far-Western Blot Analysis Service to Advance Proteomics Research

Alfa Chemistry Launches a New Blog Section: Sharing Chemical Uses, Chemistry Information and News

Katie Coleman promoted to Head of Ashfield Event Experiences US, part of Inizio Engage XD